Seven weeks before Merck & Co. pulled the arthritis drug Vioxx off the market because of safety concerns, federal drug regulators downplayed the significance of scientific findings citing the increased risks, documents released Thursday show.
Dr. David Graham, associate director for science in the drug safety division of the Food and Drug Administration, by early August had notified his supervisors that a study of Vioxx showed patients on the starting dose had 50 percent greater risk of cardiac arrest than those on competitor Celebrex.
